261 related articles for article (PubMed ID: 17261234)
21. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
[TBL] [Abstract][Full Text] [Related]
22. A prediction model for bacterial etiology in acute exacerbations of COPD.
Lode H; Allewelt M; Balk S; De Roux A; Mauch H; Niederman M; Schmidt-Ioanas M
Infection; 2007 Jun; 35(3):143-9. PubMed ID: 17565454
[TBL] [Abstract][Full Text] [Related]
23. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients.
Grossman RF; Ambrusz ME; Fisher AC; Khashab MM; Kahn JB
Clin Ther; 2006 Aug; 28(8):1175-1180. PubMed ID: 16982294
[TBL] [Abstract][Full Text] [Related]
24. [A clinical study of bacterial infection in patients with chronic obstructive pulmonary disease].
Zhao M; Gu G; Liu Z; Zhang X; Xu W; Fang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Feb; 22(2):88-91. PubMed ID: 11820948
[TBL] [Abstract][Full Text] [Related]
25. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis.
Paster RZ; McAdoo MA; Keyserling CH; Nemeth MA; Tack KJ; Griffin TJ
Int J Clin Pract; 2000 Jun; 54(5):293-9. PubMed ID: 10954955
[TBL] [Abstract][Full Text] [Related]
26. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
Martinez FJ; Anzueto A
Am J Med; 2005 Jul; 118 Suppl 7A():39S-44S. PubMed ID: 15993676
[TBL] [Abstract][Full Text] [Related]
27. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.
Soler N; Agustà C; Angrill J; Puig De la Bellacasa J; Torres A
Thorax; 2007 Jan; 62(1):29-35. PubMed ID: 16928715
[TBL] [Abstract][Full Text] [Related]
28. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Niederman MS; Anzueto A; Sethi S; Choudhri S; Kureishi A; Haverstock D; Perroncel R
Respir Med; 2006 Oct; 100(10):1781-90. PubMed ID: 16531032
[TBL] [Abstract][Full Text] [Related]
29. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis.
Anzueto A; Bishai WR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):31S-38S. PubMed ID: 17349461
[TBL] [Abstract][Full Text] [Related]
30. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults.
Murray JJ; Emparanza P; Lesinskas E; Tawadrous M; Breen JD
Otolaryngol Head Neck Surg; 2005 Aug; 133(2):194-200. PubMed ID: 16087013
[TBL] [Abstract][Full Text] [Related]
32. Treatment of acute exacerbations of chronic bronchitis: antibiotic therapy.
Anzueto A
Semin Respir Crit Care Med; 2000; 21(2):97-106. PubMed ID: 16088723
[TBL] [Abstract][Full Text] [Related]
33. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model.
Canut A; MartÃn-Herrero JE; Labora A; Maortua H
J Antimicrob Chemother; 2007 Sep; 60(3):605-12. PubMed ID: 17595285
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
Amsden GW; Baird IM; Simon S; Treadway G
Chest; 2003 Mar; 123(3):772-7. PubMed ID: 12628877
[TBL] [Abstract][Full Text] [Related]
35. Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum.
Roche N; Kouassi B; Rabbat A; Mounedji A; Lorut C; Huchon G
Respiration; 2007; 74(1):19-25. PubMed ID: 16675894
[TBL] [Abstract][Full Text] [Related]
36. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
Lopez Sisniega J; Profant M; Kostrica R; Waskin H
Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
[TBL] [Abstract][Full Text] [Related]
37. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis.
Chodosh S
Chest; 2005 Jun; 127(6):2231-6. PubMed ID: 15947342
[TBL] [Abstract][Full Text] [Related]
39. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2007 Nov; 30(5):415-21. PubMed ID: 17768034
[TBL] [Abstract][Full Text] [Related]
40. Antibiotics in acute exacerbations of chronic bronchitis.
Sethi S
Expert Rev Anti Infect Ther; 2010 Apr; 8(4):405-17. PubMed ID: 20377336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
